FiercePharmaOriginal article
{"a":[{"_":"BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts","$":{"href":"/pharma/biomarin-cuts-voxzogo-studies-children-noonan-syndrome-amid-growing-competition","hreflang":"en"}}]}
VoxzogoNegative
AI Analysis
Summary
BioMarin announced discontinuation of Voxzogo development for children with Noonan syndrome, citing competitive pressure and shifting treatment landscape. This represents a strategic retreat from the indication as competition increases in this rare disease space.
Outcome Details
BioMarin discontinued development of Voxzogo for children with Noonan syndrome due to shifting treatment landscape and growing competition
Importance:4/10
Sentiment:
-0.60
development discontinuationrare diseasecompetitive pressurepediatric indication
Related Companies
Read the original article
Published by FiercePharma on September 15, 2026 1:02 PM